NZ768098A - Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders - Google Patents
Continuous administration of pharmaceutical composition for treatment of neurodegenerative disordersInfo
- Publication number
- NZ768098A NZ768098A NZ768098A NZ76809819A NZ768098A NZ 768098 A NZ768098 A NZ 768098A NZ 768098 A NZ768098 A NZ 768098A NZ 76809819 A NZ76809819 A NZ 76809819A NZ 768098 A NZ768098 A NZ 768098A
- Authority
- NZ
- New Zealand
- Prior art keywords
- pharmaceutical composition
- treatment
- combinations
- neurodegenerative disorders
- continuous administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1850327 | 2018-03-23 | ||
| PCT/SE2019/050260 WO2019182506A1 (en) | 2018-03-23 | 2019-03-22 | Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ768098A true NZ768098A (en) | 2025-12-19 |
Family
ID=66041617
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ768098A NZ768098A (en) | 2018-03-23 | 2019-03-22 | Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11547689B2 (https=) |
| EP (1) | EP3768263B1 (https=) |
| JP (1) | JP7485874B2 (https=) |
| KR (2) | KR20200136008A (https=) |
| CN (2) | CN118121710A (https=) |
| AU (1) | AU2019237857B2 (https=) |
| ES (1) | ES3053690T3 (https=) |
| HR (1) | HRP20251502T1 (https=) |
| IL (1) | IL277553B2 (https=) |
| MY (1) | MY199846A (https=) |
| NZ (1) | NZ768098A (https=) |
| PH (1) | PH12020551527A1 (https=) |
| PL (1) | PL3768263T3 (https=) |
| RS (1) | RS67469B1 (https=) |
| SG (1) | SG11202009215PA (https=) |
| WO (1) | WO2019182506A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113197851A (zh) | 2015-05-06 | 2021-08-03 | 辛纳吉勒公司 | 包含药物粒子的药用悬浮液、用于其配给的装置、以及其使用方法 |
| EP3768263B1 (en) | 2018-03-23 | 2025-10-29 | LobSor Pharmaceuticals Aktiebolag | Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9004348D0 (en) | 1990-02-27 | 1990-04-25 | Orion Yhtymae Oy | New use of catechol derivatives and their physiologically acceptable salts and esters |
| SE9203594D0 (sv) | 1992-11-30 | 1992-11-30 | Christer Nystroem | Laekemedel i dispersa system |
| US20080118556A1 (en) * | 1998-11-02 | 2008-05-22 | Elan Corporation, Plc | Modified Release of Compositions Containing a Combination of Carbidopa, Levodopa and Entacapone |
| FI109453B (fi) | 1999-06-30 | 2002-08-15 | Orion Yhtymae Oyj | Farmaseuttinen koostumus |
| DE602004031134D1 (de) | 2003-08-29 | 2011-03-03 | Transform Pharmaceuticals Inc | Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa |
| EP1796687A2 (en) * | 2004-09-14 | 2007-06-20 | Elixir Pharmaceuticals, Inc. | Combination therapy for controlled carbohydrate digestion |
| CN101132777A (zh) * | 2004-12-20 | 2008-02-27 | 科利吉姆制药公司 | 用于睡眠障碍的药物组合物 |
| US20060222703A1 (en) | 2005-04-01 | 2006-10-05 | Iprbox Oy | Pharmaceutical composition and preparation method thereof |
| WO2007138086A1 (en) | 2006-05-31 | 2007-12-06 | Solvay Pharmaceuticals Gmbh | Long term 24 hour intestinal administration of levodopa/carbidopa |
| US8741342B2 (en) * | 2006-10-30 | 2014-06-03 | Wockhardt Research Centre | Pharmaceutical compositions comprising entacapone, levodopa, and carbidopa |
| EP2252284B1 (en) | 2008-02-06 | 2011-05-25 | Wockhardt Research Centre | Pharmaceutical compositions of entacapone, levodopa and carbidopa with improved bioavailability |
| CN102202656A (zh) * | 2008-08-15 | 2011-09-28 | 蒂宝制药公司 | 治疗和预防cns障碍的胃滞留药用组合物 |
| EA026419B1 (ru) | 2010-03-04 | 2017-04-28 | Орион Корпорейшн | Применение леводопы, карбидопы и энтакапона для лечения болезни паркинсона |
| PT2640358T (pt) | 2010-11-15 | 2018-02-23 | Neuroderm Ltd | Administração contínua de l-dopa, inibidores de dopa descarboxilase, inibidores de catecol-o-metil transferase e composições para os mesmos |
| WO2012147099A1 (en) | 2011-04-25 | 2012-11-01 | Suven Nishtaa Pharma Pvt. Ltd. | Pharmaceutical compositions of levodopa, carbidopa and entacapone |
| JP6622310B2 (ja) * | 2014-09-04 | 2019-12-18 | ロブソル・ファーマシューティカルズ・アクチボラグＬｏｂｓｏｒ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ａｋｔｉｅｂｏｌａｇ | レボドパ、ドーパミン脱炭酸酵素阻害薬およびｃｏｍｔ阻害薬を含む医薬組成物ならびにその投与方法 |
| US10555922B2 (en) * | 2015-09-04 | 2020-02-11 | Lobsor Pharmaceuticals Aktiebolag | Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor |
| EP3768263B1 (en) * | 2018-03-23 | 2025-10-29 | LobSor Pharmaceuticals Aktiebolag | Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders |
-
2019
- 2019-03-22 EP EP19715590.6A patent/EP3768263B1/en active Active
- 2019-03-22 KR KR1020207030580A patent/KR20200136008A/ko not_active Ceased
- 2019-03-22 CN CN202410175227.3A patent/CN118121710A/zh active Pending
- 2019-03-22 JP JP2020551353A patent/JP7485874B2/ja active Active
- 2019-03-22 US US17/040,511 patent/US11547689B2/en active Active
- 2019-03-22 RS RS20251225A patent/RS67469B1/sr unknown
- 2019-03-22 MY MYPI2020004885A patent/MY199846A/en unknown
- 2019-03-22 KR KR1020257008573A patent/KR20250043584A/ko active Pending
- 2019-03-22 HR HRP20251502TT patent/HRP20251502T1/hr unknown
- 2019-03-22 ES ES19715590T patent/ES3053690T3/es active Active
- 2019-03-22 IL IL277553A patent/IL277553B2/en unknown
- 2019-03-22 SG SG11202009215PA patent/SG11202009215PA/en unknown
- 2019-03-22 PL PL19715590.6T patent/PL3768263T3/pl unknown
- 2019-03-22 AU AU2019237857A patent/AU2019237857B2/en active Active
- 2019-03-22 CN CN201980034384.XA patent/CN112261940B/zh active Active
- 2019-03-22 WO PCT/SE2019/050260 patent/WO2019182506A1/en not_active Ceased
- 2019-03-22 NZ NZ768098A patent/NZ768098A/en unknown
-
2020
- 2020-09-22 PH PH12020551527A patent/PH12020551527A1/en unknown
-
2022
- 2022-11-04 US US17/981,092 patent/US12251368B2/en active Active
-
2025
- 2025-02-12 US US19/051,884 patent/US20250213518A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL277553A (en) | 2020-11-30 |
| CN112261940B (zh) | 2024-02-27 |
| US12251368B2 (en) | 2025-03-18 |
| HRP20251502T1 (hr) | 2026-02-13 |
| KR20200136008A (ko) | 2020-12-04 |
| JP2021519272A (ja) | 2021-08-10 |
| AU2019237857B2 (en) | 2024-11-21 |
| EP3768263A1 (en) | 2021-01-27 |
| US20230157989A1 (en) | 2023-05-25 |
| EP3768263B1 (en) | 2025-10-29 |
| ES3053690T3 (en) | 2026-01-23 |
| PL3768263T3 (pl) | 2026-01-26 |
| US20250213518A1 (en) | 2025-07-03 |
| US20210015782A1 (en) | 2021-01-21 |
| AU2019237857A1 (en) | 2020-10-08 |
| US11547689B2 (en) | 2023-01-10 |
| IL277553B2 (en) | 2024-11-01 |
| CN112261940A (zh) | 2021-01-22 |
| JP7485874B2 (ja) | 2024-05-17 |
| SG11202009215PA (en) | 2020-10-29 |
| CN118121710A (zh) | 2024-06-04 |
| EP3768263C0 (en) | 2025-10-29 |
| KR20250043584A (ko) | 2025-03-28 |
| MY199846A (en) | 2023-11-24 |
| PH12020551527A1 (en) | 2021-07-19 |
| WO2019182506A1 (en) | 2019-09-26 |
| IL277553B1 (en) | 2024-07-01 |
| RS67469B1 (sr) | 2025-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024001203A (es) | Combinaciones de agonistas de receptores de hormona tiroidea (tr-\03b2) con moduladores metabolicos para usarse en tratar enfermedades del higado graso. | |
| CY1120005T1 (el) | Συνεχης χορηγηση αναστολεων l-ντοπα, αποκαρβοξυλασης ντοπα, αναστολεων κατεχολ-ο-μεθυλ τρανσφερασης και συνθεσεις αυτων | |
| WO2011107653A3 (en) | Use of levodopa, carbidopa and entacapone for treating parkinson's disease | |
| MX365206B (es) | Metodo para el tratamiento de la enfermedad de parkinson. | |
| EP4272818A3 (en) | Thrombolytic agent for the treatment of thromboembolism | |
| MX2021011928A (es) | Composiciones y metodos para el tratamiento de enfermedades o trastornos asociados con kras. | |
| AR124078A1 (es) | Método para el tratamiento de la enfermedad de parkinson | |
| AU2017261286A1 (en) | Treatment of hair loss disorders with deuterated JAK inhibitors | |
| ZA202000028B (en) | Use of vibegron to treat overactive bladder | |
| MX2025001920A (es) | Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina | |
| RU2018110580A (ru) | Проникающее в мозг производное оксима хромона для терапии леводопа-индуцированной дискинезии | |
| NZ768098A (en) | Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders | |
| AU2018282105A1 (en) | Dosing of vibegron for treatment of overactive bladder | |
| MX2021005904A (es) | Inhibidores de la ácido alfa-amino-beta-carboximucónico semialdehído descarboxilasa. | |
| BR112019002461A2 (pt) | regime de dosagem para tratamento de tumores sólidos | |
| EP4578461A3 (en) | Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa | |
| JP2019529569A5 (https=) | ||
| WO2006002096A3 (en) | Low doses of l-citrulline for treating diseases | |
| MX2022012693A (es) | Composicion que comprende metilfolato. | |
| MX388067B (es) | Combinacion sinergica de s-ketorolaco y pregabalina en una composicion farmaceutica para el tratamiento del dolor neuropatico | |
| MX2021007324A (es) | Terapia oral con acido 6,8-bis-benciltio-octanoico. | |
| MX2022011000A (es) | Metodos y composiciones para identificar y tratar canceres sensibles a los inhibidores de glutaminasa. | |
| EP3823607A4 (en) | ADMINISTRATION OF LEVODOPA AND DOPA DECARBOXYLASE INHIBITOR INTO THE RESPIRATORY TRACT FOR THE TREATMENT OF PARKINSON'S DISEASE | |
| HK1246687A1 (zh) | 治疗与帕金逊症治疗相关的运动失调及其副作用的方法 | |
| US20090012170A1 (en) | Treatment of symptoms of motor dysfunction |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed |